Epidermal growth factor receptor (EGFR)-2/ HER-2 (EGFR) is one of the major oncogenes recognized in a variety of human cancer including breast cancer . This receptor plays important role in regulation of cell growth, cell survival, and differentiation through multiple signaling pathways which play important role in cellular proliferation and differentiation. This receptor consists of several transmembrane glycoproteins. The receptor family is composed of four main members commonly known as HER-1, HER-2, HER-3, and HER-4, also called ErbB1, ErbB2, ErbB3, and ErbB4, respectively . Activating mutations of EGFR results in uncontrolled cell proliferation and survival. The mutations of EGFR have been reported in several types of human cancers especially lung adenocarcinoma, head and neck squamous cell carcinoma and colorectal carcinoma and breast cancer. Therefore, there have been considerable interest to target EGFR using drugs with potential EGFR inhibitory action .